TW202108624A - 投予抗ｃｄ３８抗體的方法 - Google Patents

投予抗ｃｄ３８抗體的方法 Download PDF

Info

Publication number
TW202108624A
TW202108624A TW109116104A TW109116104A TW202108624A TW 202108624 A TW202108624 A TW 202108624A TW 109116104 A TW109116104 A TW 109116104A TW 109116104 A TW109116104 A TW 109116104A TW 202108624 A TW202108624 A TW 202108624A
Authority
TW
Taiwan
Prior art keywords
antibody
infusion
administered
hour
individual
Prior art date
Application number
TW109116104A
Other languages
English (en)
Chinese (zh)
Inventor
赫洛伊斯 奧黛特
席維亞 瑪莉恩
桑布拉諾 法蘭克 坎帕納
Original Assignee
法商賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲公司 filed Critical 法商賽諾菲公司
Publication of TW202108624A publication Critical patent/TW202108624A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW109116104A 2019-05-14 2020-05-14 投予抗ｃｄ３８抗體的方法 TW202108624A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US62/847,825 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US62/860,739 2019-06-12
US201962899088P 2019-09-11 2019-09-11
US62/899,088 2019-09-11
EP20305223.8 2020-03-03
EP20305223 2020-03-03

Publications (1)

Publication Number Publication Date
TW202108624A true TW202108624A (zh) 2021-03-01

Family

ID=71094805

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109116104A TW202108624A (zh) 2019-05-14 2020-05-14 投予抗ｃｄ３８抗體的方法

Country Status (15)

Country Link
US (1) US20210171650A1 (https=)
EP (1) EP3969004A1 (https=)
JP (2) JP7801132B2 (https=)
KR (1) KR20220008305A (https=)
CN (2) CN120501855A (https=)
AU (1) AU2020274169A1 (https=)
BR (1) BR112021022503A2 (https=)
CA (1) CA3140034A1 (https=)
CO (1) CO2021016606A2 (https=)
IL (1) IL287832A (https=)
MA (1) MA55967A (https=)
MX (1) MX2021013910A (https=)
SG (1) SG11202112513YA (https=)
TW (1) TW202108624A (https=)
WO (1) WO2020232173A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
KR20210030411A (ko) * 2018-07-10 2021-03-17 사노피 Cd38 및 tgf-베타를 표적으로 하는 암에 대한 병용 요법
EP3980064A1 (en) * 2019-06-10 2022-04-13 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
AU2022253256A1 (en) * 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd38-targeted antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法

Also Published As

Publication number Publication date
BR112021022503A2 (pt) 2021-12-28
CO2021016606A2 (es) 2022-04-29
JP7801132B2 (ja) 2026-01-16
EP3969004A1 (en) 2022-03-23
CN114080233A (zh) 2022-02-22
JP2022532356A (ja) 2022-07-14
MA55967A (fr) 2022-03-23
CN120501855A (zh) 2025-08-19
MX2021013910A (es) 2022-03-11
US20210171650A1 (en) 2021-06-10
CA3140034A1 (en) 2020-11-19
AU2020274169A1 (en) 2022-01-20
JP2025166108A (ja) 2025-11-05
WO2020232173A1 (en) 2020-11-19
KR20220008305A (ko) 2022-01-20
SG11202112513YA (en) 2021-12-30
IL287832A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
TW202108624A (zh) 投予抗ｃｄ３８抗體的方法
US20240190984A1 (en) Methods of treating multiple myeloma
CN110366562A (zh) 使用抗pd-l1抗体和抗雄激素治疗癌症的方法
US20200317800A1 (en) Obinutuzumab treatment of a dlbcl patient subgroup
TW202541838A (zh) 抗ｃｄ３８抗體在治療新診斷的多發性骨髓瘤中之用途
TWI887310B (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途
TWI870415B (zh) 使用抗cd38抗體之組合療法
TWI922320B (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途
US20250134997A1 (en) Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy in ctdna high risk patients
RU2838203C2 (ru) Способы лечения множественной миеломы
CA3048245A1 (en) Methods of administering anti-cd38 antibody
TW202610683A (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途